Journal
GENES
Volume 13, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/genes13101760
Keywords
ScRNA-seq; prognostic model; SPP1; immune related signatures; pancreatic cancer
Categories
Funding
- Natural Science Foundation of China [82171722, 81871954]
- Beijing Municipal Natural Science Foundation [7212111]
Ask authors/readers for more resources
This study utilized single-cell RNA sequencing and database information to identify reliable markers for malignant ductal cells in pancreatic ductal adenocarcinoma (PDAC) and developed a potential prognostic model based on immune-related signatures.
There are no reliable biomarkers for early diagnosis or prognosis evaluation in pancreatic ductal adenocarcinoma (PDAC). Multiple scRNA-seq datasets for PDAC were retrieved from online databases and combined with scRNA-seq results from our previous study. The malignant ductal cells were identified through calculating copy number variation (CNV) scores. The robust markers of malignant ductal cells in PDAC were found. Five immune-related signatures, including SPP1, LINC00683, SNHG10, LINC00237, and CASC19, were used to develop a risk score formula to predict the overall survival of PDAC patients. We also constructed an easy-to-use nomogram, combining risk score, N stage, and margin status. The expression level of SPP1 was related to the prognosis and immune regulators. We found that SPP1 was mainly expressed in ductal cells and macrophages in PDAC. In conclusion, we constructed a promising prognostic model based on immune-related signatures for PDAC using scRNA-seq and TCGA_PAAD datasets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available